Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.43 |
| ▸ | ANXA2 | P07355 | 1/20 | 0.42 |
| ▸ | S100A10 | P60903 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9418077 | 1.00 | MAPK1 (0.74) | MAPK1CYP3A4TSHRALDH1A1ALOX15 | |
| SCHEMBL10813732 | 0.86 | CYP3A4 (1.00) | MAPK1CYP3A4TSHRALDH1A1ALOX15 | |
| SCHEMBL3411276 | 0.86 | MAOA (0.64) | MAPK1CYP3A4TSHRALDH1A1ALOX15 | |
| SCHEMBL9647870 | 0.86 | CYP3A4 (1.00) | MAPK1CYP3A4TSHRALDH1A1ALOX15 | |
| SCHEMBL4123832 | 0.86 | MAOA (0.64) | MAPK1CYP3A4TSHRALDH1A1ALOX15 | |
| 4,4'-Thiodianiline SCHEMBL49068 | 0.86 | CYP3A4 (1.00) | MAPK1CYP3A4TSHRALDH1A1ALOX15 | |
| SCHEMBL9485453 | 0.86 | CYP3A4 (1.00) | MAPK1CYP3A4TSHRALDH1A1ALOX15 | |
| SCHEMBL9649030 | 0.86 | CYP3A4 (1.00) | MAPK1CYP3A4TSHRALDH1A1ALOX15 | |
| SCHEMBL9485438 | 0.86 | CYP3A4 (1.00) | MAPK1CYP3A4TSHRALDH1A1ALOX15 | |
| SCHEMBL9649049 | 0.86 | CYP3A4 (1.00) | MAPK1CYP3A4TSHRALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5328980-A | Promoters with halothiophenol compounds and polar organic compounds | PHILLIPS PETROLEUM COMPANY (US) | 1994-07-12 | — | — | US | claimed |
| EP-0604778-A2 | Method of preparing poly(arylene sulfide)polymers, polymers, and polymer blends | PHILLIPS PETROLEUM COMPANY (US) | 1994-07-06 | — | — | EP | claimed |
| JP-6234854-A | — | — | None | — | — | JP | disclosed |
| EP-2611777-B1 | N-(4-{[PYRIDIN-3-YL-METHYL)CARBAMOYL]AMINO}BENZENE-SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM LLC (US) | 2016-05-11 | — | — | EP | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2007092190-A2 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| CN-101018761-A | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060135786-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHAMACEUTICALS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| JP-H06234854-A | PREPARATION OF ARYLENE SULFIDE POLYMER | PHILLIPS PETROLEUM CO | 1994-08-23 | — | — | JP | disclosed |
| US-5328980-A | Promoters with halothiophenol compounds and polar organic compounds | PHILLIPS PETROLEUM COMPANY (US) | 1994-07-12 | — | — | US | disclosed |
| EP-0604778-A2 | Method of preparing poly(arylene sulfide)polymers, polymers, and polymer blends | PHILLIPS PETROLEUM COMPANY (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0102476-B1 | METHOD OF MODULATING THE IMMUNE RESPONSE SYSTEM IN MAMMALS | AMERICAN CYANAMID COMPANY (US) | 1986-11-05 | — | — | EP | disclosed |
| US-4605713-A | Process for the production of polyarylene sulphides with functional end groups | BAYER AKTIENGESELLSCHAFT (DE) | 1986-08-12 | — | — | US | disclosed |
| US-4605732-A | Process for the production of polyarylene sulphides with functional end groups | BAYER AKTIENGESELLSCHAFT (DE) | 1986-08-12 | — | — | US | disclosed |
| US-4532349-A | 2-Amino-4'(phenylsulfonyl) acetanilides | AMERICAN CYANAMID COMPANY (US) | 1985-07-30 | — | — | US | disclosed |
| EP-0102476-A1 | Method of modulating the immune response system in mammals | AMERICAN CYANAMID COMPANY (US) | 1984-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | MAPK1 1028/4885CYP3A4 4654/4885TSHR 642/4885 |
| US-20060135786-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | MAPK1 1028/4885CYP3A4 4654/4885TSHR 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.